Ticker brief
BLSM
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
4
crowd 14d
+0.33
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-18 → 2026-08-26 · now +0.30 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @IPODave | B | +1.63 | 3 | +0.33 |
| @theflynews | C | · | 1 | +0.50 |
| @OzmosiHealth | C | · | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.10 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-26 | @IPODave | +0.30 | Trim BLSM and LGTO after bumps while retaining some for next week's targets. — Plans partial sales after price bumps while retaining exposure into analyst recommendations. | · | tweet ↗ |
| 2026-08-22 | @BiopharmIQ | +0.10 | Weekly biotech recap aggregates clinical, AI, pricing and deal catalysts across directly discussed names. | · | tweet ↗ |
| 2026-08-21 | @IPODave | +0.70 | Will add more BLSM on any breakout and hold long term. — Author is interested in BLSM, cites fair value and management, and plans to add on a breakout. | · | tweet ↗ |
| 2026-08-21 | @IPODave | +0.00 | Watch list for expected analyst coverage over the next couple of weeks. | · | tweet ↗ |
| 2026-08-18 | @OzmosiHealth | +0.50 | FDA granted Fast Track designation to BH-30643 for advanced EGFR-mutant lung cancer. | · | tweet ↗ |
| 2026-08-18 | @theflynews | +0.50 | FDA granted fast-track designation to BlossomHill's BH-30643. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.